Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today said a jury found in its favor in the Glynn v. Merck case in the U.S. District Court for the District of New Jersey. In the case, the plaintiff claimed she used FOSAMAX and subsequently suffered an atypical femur fracture. Language:  English Contact HTML:  MerckMedia Contact:Lainie Keller, 908-423-4187orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: Tags: Corporate News Source Type: news